Paraquat

The Paraquat docket, built on claims that agricultural and occupational exposure to the herbicide paraquat is linked to an elevated risk of Parkinson's disease, carries 6,666 pending actions roughly five years after centralization — a large and still-growing claims population reflecting both widespread historical use of the product and the long latency typical of neurodegenerative-disease claims. The litigation moved through a substantial bellwether-preparation process, with a court selecting a slate of bellwether cases and setting a trial track, before the parties reached a negotiated settlement agreement that displaced the need for the first scheduled bellwether trial to proceed to verdict.

For a funder, that sequence — extensive bellwether preparation followed by a negotiated resolution reached before trial — is meaningfully informative even without a jury verdict on the merits: it reflects both sides having tested their positions through extensive expert discovery on general causation (agricultural chemical exposure and neurodegenerative disease mechanisms) before choosing settlement over the uncertainty of a bellwether verdict. That said, a negotiated agreement reached in this manner does not necessarily resolve every claim in the docket, and diligence on any individual Paraquat claim should confirm that specific claimant's relationship to any settlement structure, including exposure-history and diagnosis documentation requirements.

Medical-lien considerations are meaningful here given the ongoing treatment, monitoring, and progressive care typically associated with a Parkinson's disease diagnosis, and should be modeled against the claimant's expected recovery and treatment trajectory.

Given the docket's substantial scale and the settlement activity already underway, portfolio-level inventory finance is a reasonable structure for a firm with meaningful volume, with underwriting attentive to each claimant's exposure documentation and settlement-eligibility status. Criterica Capital's mass-tort finance and medical-lien receivables products apply here.

Criterica Intelligence's structural brief covers the bellwether-to-settlement sequence in this docket in more depth.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.